<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03419650</url>
  </required_header>
  <id_info>
    <org_study_id>AC0014</org_study_id>
    <nct_id>NCT03419650</nct_id>
  </id_info>
  <brief_title>Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)</brief_title>
  <acronym>CLIPS</acronym>
  <official_title>Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRIS Research and Development, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>IRIS Research and Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate the clinical value of Acthar TM in patients with active Psoriatic Arthritis who&#xD;
      lack adequate response to DMARDS, and the quantification of response by clinical, serologic&#xD;
      and structural parameters.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an investigator initiated study (IIS) single arm treatment, single center where&#xD;
      patients will receive active treatment with ActharTM 80 units twice weekly for 4 weeks&#xD;
      followed by 40 units twice weekly until week 12.&#xD;
&#xD;
      2-End points:&#xD;
&#xD;
      1.Primary Clinical Endpoint&#xD;
&#xD;
      1. To demonstrate the efficacy of Acthar for the treatment of patients with active psoriatic&#xD;
      arthritis and who have not had an adequate response to non-biological DMARDs based on the&#xD;
      proportion of subjects achieving a 20% improvement in the number of tender and number of&#xD;
      swollen joints, and a 20% improvement in three of the following five criteria: patient global&#xD;
      assessment, physician global assessment, Health Assessment Questionnaire (HAQ), visual analog&#xD;
      pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP) as described by&#xD;
      American College of Rheumatology (ACR) 20 at week 12.&#xD;
&#xD;
      [Time Frame: 12 weeks]&#xD;
&#xD;
      2.Primary Imaging Endpoints&#xD;
&#xD;
        1. The improvement of the total DEMRIQ*-Volume score of synovial inflammation measured in&#xD;
           the Metacarpophalangeal (MCP), proximal interphalangeal (PIP) and the distal&#xD;
           interphalangeal (DIP) joints. [Time Frame: baseline to week 24]&#xD;
&#xD;
           [Time Frame: baseline to week 24]&#xD;
&#xD;
        2. Secondary Outcome Measures:&#xD;
&#xD;
      Secondary Imaging Endpoints&#xD;
&#xD;
      1. The improvement in PSAMRIS* Synovitis score in the Metacarpophalangeal (MCP), proximal&#xD;
      interphalangeal (PIP) and the distal interphalangeal (DIP) joints. [Time Frame: baseline to&#xD;
      week 24]&#xD;
&#xD;
      [Time Frame: baseline to week 24]&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 20, 2018</start_date>
  <completion_date type="Actual">August 25, 2021</completion_date>
  <primary_completion_date type="Actual">August 25, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>treatment arm will then be observed.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Clinical Endpoint</measure>
    <time_frame>12 weeks</time_frame>
    <description>1. To demonstrate the efficacy of Acthar for the treatment of patients with active psoriatic arthritis and who have not had an adequate response to non-biological DMARDs based on the proportion of subjects achieving a 20% improvement in the number of tender and number of swollen joints, and a 20% improvement in three of the following five criteria: patient global assessment, physician global assessment, Health Assessment Questionnaire (HAQ), visual analog pain scale, and erythrocyte sedimentation rate or C-reactive protein (CRP) as described by American College of Rheumatology (ACR) 20 at week 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Imaging Endpoints</measure>
    <time_frame>baseline to week 24</time_frame>
    <description>1. The improvement of the total DEMRIQ*-Volume score of synovial inflammation measured in the Metacarpophalangeal (MCP), proximal interphalangeal (PIP) and the distal interphalangeal (DIP) joints. [Time Frame: baseline to week 24]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Imaging Endpoints</measure>
    <time_frame>baseline to week 24</time_frame>
    <description>1. The improvement in PSAMRIS* Synovitis score in the Metacarpophalangeal (MCP), proximal interphalangeal (PIP) and the distal interphalangeal (DIP) joints. [Time Frame: baseline to week 24]</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>treatment arm for 12 weeks followed by observation period of 12 weeks, and a bone density at week 52.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACTHar</intervention_name>
    <description>Actharâ„¢ 80 units twice a week for 4 weeks followed by 40 units twice a week until week 12.</description>
    <arm_group_label>Treatment arm</arm_group_label>
    <other_name>acthar gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed written informed consent before any study-related procedure is undertaken that&#xD;
             is not part of the standard subject management&#xD;
&#xD;
          2. Subjects are willing to comply with the structure of the study, such as visits,&#xD;
             treatment plan, laboratory and imaging studies.&#xD;
&#xD;
             Clinical evidence of psoriatic arthritis defined by at least 6 months of CASPAR&#xD;
             defined criteria (evidence of current psoriasis, a personal history of psoriasis, or a&#xD;
             family history of psoriasis. Current psoriasis is defined as psoriatic skin or scalp&#xD;
             disease present today as judged by a rheumatologist or dermatologist. A personal&#xD;
             history of psoriasis is defined as a history of psoriasis that may be obtained from a&#xD;
             patient, family physician, dermatologist, rheumatologist, or other qualified health&#xD;
             care provider. A family history of psoriasis is defined as a history of psoriasis in a&#xD;
             first- or second-degree relative according to patient report, and the number of tender&#xD;
             and swollen joints as later specified. Typical psoriatic nail dystrophy including&#xD;
             onycholysis, pitting, and hyperkeratosis observed on current physical examination.&#xD;
&#xD;
             c. A negative test result for the presence of rheumatoid factor by any method,&#xD;
             according to the local laboratory reference range.&#xD;
&#xD;
             d. Either current dactylitis, defined as swelling of an entire digit, or a history of&#xD;
             dactylitis recorded by a rheumatologist.&#xD;
&#xD;
             e. Radiographic evidence of juxtaarticular new bone formation, appearing as&#xD;
             ill-defined ossification near joint margins (but excluding osteophyte formation) on&#xD;
             plain radiographs of the hand or foot.&#xD;
&#xD;
             Current psoriasis is assigned a score of 2; all other features are assigned a score of&#xD;
             1.&#xD;
&#xD;
             The subject must have active arthritis at both screening and baseline, as defined by&#xD;
             having both:&#xD;
&#xD;
               -  Tender/painful joints on motion (out of 68 joints assessed); and;&#xD;
&#xD;
               -  Swollen joints (out of 66 joints assessed). The subject must have active Plaque&#xD;
                  Psoriasis, which has been diagnosed, or confirmed by a rheumatologist or&#xD;
                  dermatologist and the ability to use skin biopsy as a diagnostic method.&#xD;
&#xD;
          3. Previous use of DMARDS:&#xD;
&#xD;
             The practices for the administration of DMARD therapy, including laboratory testing,&#xD;
             contraceptive requirements, follow-up care and contraindications should be performed&#xD;
             according to local standards of care such as the ACR recommendations for monitoring&#xD;
             for the duration of the study. Subjects should remain on a stable dose of that&#xD;
             traditional DMARD throughout the course of the study.&#xD;
&#xD;
             Methotrexate: Maximum dose of 15 mg/week. Minimum duration of therapy 3 months and&#xD;
             dose stable for 4 weeks prior to first dose of the study. Subjects on methotrexate&#xD;
             should be on an adequate and stable dose of folate supplementation.&#xD;
&#xD;
             Sulfasalazine: Maximum dose of 3 gm/day. Minimum duration of therapy 2 months and dose&#xD;
             stable for 4 weeks prior to first dose of study drug.&#xD;
&#xD;
             Leflunomide: Maximum dose of 20 mg/day. Minimum duration of therapy 4 months and dose&#xD;
             stable for 4 weeks prior to first dose of study drug.&#xD;
&#xD;
             Plaquenil Azathioprine&#xD;
&#xD;
          4. Concomitant treatments:&#xD;
&#xD;
             Corticosteroids up to 10 mg/day prednisone or prednisone equivalent are allowed for 4&#xD;
             weeks stable dose before the study and can be tapered according to the investigator&#xD;
             criteria of clinical response. NSAIDS and COX 2 medications can be used in clinically&#xD;
             accepted doses and in stable doses 4 weeks prior to screening. Topical keratolytics&#xD;
             such as corticosteroids, tars, anthralin, vitamin D analogs, and retinoids must be&#xD;
             discontinued 2 weeks prior to the screening date. Non-medicated emollients including&#xD;
             1% hydrocortisone for palms and soles are allowed. UV light therapy needs to be&#xD;
             discontinued 2 weeks prior to screening, and PUVA 4 weeks prior to screening.&#xD;
&#xD;
          5. A male participant must agree to use and to have their female partners use a highly&#xD;
             effective form of contraception, one day before the first dose of study treatment (as&#xD;
             appropriate), during the treatment period, and refrain from donating sperm during this&#xD;
             period.&#xD;
&#xD;
          6. A female participant is eligible to participate if she is not pregnant, not&#xD;
             breastfeeding, and at least one of the following conditions applies: age related&#xD;
             amenorrhea for at least one year, and increased follicle-stimulating hormone (FSH) &gt;40&#xD;
             Miu/Ml or who have undergone hysterectomy or bilateral oophorectomy are exempt from&#xD;
             pregnancy testing.&#xD;
&#xD;
        A woman of childbearing potential is defined as a female capable of becoming pregnant. It&#xD;
        is also defined as any female who has experienced menarche and is not permanently sterile&#xD;
        or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses&#xD;
        without alternative medical cause.&#xD;
&#xD;
        Women of childbearing potential must agree to at least one method of birth control: a&#xD;
        barrier method together or alone with a highly effective method to prevent pregnancy four&#xD;
        weeks prior to randomization, throughout the study.&#xD;
&#xD;
        The definition of highly effective contraception includes:&#xD;
&#xD;
          -  Combined (estrogen and progestogen containing) hormonal contraception associated with&#xD;
             inhibition of ovulation; oral, intravaginal or transdermal,&#xD;
&#xD;
          -  Progestogen-only hormonal contraception associated with inhibition of ovulation; oral,&#xD;
             injectable or implantable,&#xD;
&#xD;
          -  Intrauterine device,&#xD;
&#xD;
          -  Intrauterine hormone-releasing system,&#xD;
&#xD;
          -  Bilateral tubal occlusion,&#xD;
&#xD;
          -  Vasectomized partner, or&#xD;
&#xD;
          -  Sexual abstinence. b. Supplementary barrier methods include:&#xD;
&#xD;
          -  Male or female condom with or without spermicide, or&#xD;
&#xD;
          -  Cap, diaphragm or sponge with spermicide, c. Men must agree to use and have their&#xD;
             female partners use a barrier method together with a highly effective contraceptive&#xD;
             method as defined above.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other forms of psoriasis than plaque psoriasis.&#xD;
&#xD;
          2. Any person in direct relation to the study site such as employees or family members.&#xD;
&#xD;
          3. Breast feeding females, pregnant females or women in childbearing age not using&#xD;
             adequate contraception.&#xD;
&#xD;
          4. Subjects participating in other concomitant investigational protocols.&#xD;
&#xD;
          5. Concurrent forms of severe, progressive disease such as renal, hepatic, hematological,&#xD;
             gastrointestinal, pulmonary, neurologic and metabolic.&#xD;
&#xD;
          6. Blood cell count below 9g/dl of hemoglobin, wbc count of less than 3000/cubic&#xD;
             millimeters, neutropenia of less than 1500/cubic millimeter, platelet count below&#xD;
             100,000/cubic millimeter.&#xD;
&#xD;
          7. Creatinine clearance of less than 40ml/min&#xD;
&#xD;
          8. Total bilirubin or transaminases 1.5 the normal value.&#xD;
&#xD;
          9. Known immunodeficiency&#xD;
&#xD;
         10. Subjects with other known autoimmune rheumatic disorder such as (Systemic Lupus&#xD;
             Erythematosus (SLE), Mixed Connective Tissue Disease (MCTD)), or other known&#xD;
             inflammatory disorders like gout, Lyme disease, infectious disorders.&#xD;
&#xD;
         11. History of Infected prosthesis&#xD;
&#xD;
         12. History of lymphoprolipherative disorder&#xD;
&#xD;
         13. History of recurrent disseminated herpetic infections.&#xD;
&#xD;
         14. Active infections, recent hospitalization for a condition requiring intravenous&#xD;
             antibiotics, for three months since discharge.&#xD;
&#xD;
         15. Any form of biologic agent or patients who are active on chemotherapy or chemotherapy&#xD;
             or any biologic within 6 months of the last treatment dose.&#xD;
&#xD;
         16. Alcohol abuse unless documented remission for more than 6 months&#xD;
&#xD;
         17. Acute psychiatric disorders or conditions that can alter the judgment of the subject.&#xD;
&#xD;
         18. Active Hepatitis B, and/or Hepatitis C.&#xD;
&#xD;
         19. Within one month prior to Screening, vaccination with live or live-attenuated virus&#xD;
             vaccine.&#xD;
&#xD;
         20. Allergy to porcine derived substances, participants with congestive heart failure, and&#xD;
             with osteoporosis are also excluded from the trial.&#xD;
&#xD;
        MRI related exclusion criteria In addition to the subjects matching the inclusion/exclusion&#xD;
        criteria above, patients meeting any of the below must be excluded from the study.&#xD;
&#xD;
          -  Known allergy to gadolinium or any of the excipients contained in the MRI contrast&#xD;
             agent&#xD;
&#xD;
          -  History of allergy&#xD;
&#xD;
          -  Any metal objects e.g. Shrapnel, any surgical clips, pacemakers, pins, plates, screws,&#xD;
             metal sutures or wire mesh also including uterine coil.&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Morbid Obesity (BMI &gt; 40kg/m2)&#xD;
&#xD;
          -  Cochlear implants Caution is required for patients with tattoos: the patient should&#xD;
             inform the MRI technician site staff, who will then be able to assess whether it is&#xD;
             sage for the patient to undergo the MRI scan.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IRIS Research and Development</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>January 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRIS Research and Development, LLC</investigator_affiliation>
    <investigator_full_name>Guillermo Valenzuela, MD</investigator_full_name>
    <investigator_title>Rheumatologist</investigator_title>
  </responsible_party>
  <keyword>PsA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

